Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

Following a sell-side Q&A session with Regeneron's management, the analysts received confirmation of the company's strategic emphasis on advancing its pipeline. Management's intention to shift the ...